SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D at AshTip Solution.

AshTip NewsLetter |SAN DIEGO — Weekly tirzepatide injections in adults with type 2 diabetes and overweight or obesity safely led to 12.8%-14.7% in-trial weight loss after 72 weeks in the SURMOUNT-2 pivotal trial, a finding that will likely lead to a US Food and Drug Administration (FDA) approval of

Medscape

SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D

SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D

SAN DIEGO — Weekly tirzepatide injections in adults with type 2 diabetes and overweight or obesity safely led to 12.8%-14.7% in-trial weight loss after 72 weeks in the SURMOUNT-2 pivotal trial, a finding that will likely lead to a US Food and Drug Administration (FDA) approval of a new indication for weight loss for tirzepatide.